Ilaria Tanasi

@univr.it

Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona
Azienda Ospedaliera Universitaria Integrata di Verona

Ilaria Tanasi


            Download Compact PDF  
https://researchid.co/ilaria.tanasi
40

Scopus Publications

Scopus Publications

  • Serositis as possible manifestation in MDS/AML patients with complex karyotype and TP53 mutation: case series
    Eleonora Gugole, Edoardo Tamellini, Sara Jance, Nicola Serafin, Pietro Antonini, Chiara Colato, Mauro Krampera, Isacco Ferrarini, Ilaria Tanasi
    Annals of Hematology, 2026
    Myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML) are increasingly recognized to exhibit immune dysregulation, which can occasionally present with autoinflammatory manifestations. We describe four patients with MDS/AML harboring p53 mutations and a complex karyotype who developed inflammatory serositis without infectious correlation. All patients showed clinical improvement following corticosteroid therapy.
  • Biconcave vertebral fractures as a possible distinctive feature of indolent systemic mastocytosis compared with primary osteoporosis
    Gaetano Paride Arcidiacono, Marco Onofrio Torres, Francesca Zanchetta, Sofia Testoni, Giovanni Tripepi, Alberta Cecchinato, Martin Diogo, Mor Peleg Falb, Francesca Guidolin, Irene Bertozzi, Marco Pizzi, Mauro Cancian, Riccardo Senter, Ilaria Gianesello, Francesca Caroppo, Ilaria Tanasi, Roberta Zanotti, Lorenza Belletti, Maria Fusaro, Elena Campello, Stefania Sella, Paolo Simioni, Sandro Giannini
    Osteoporosis International, 2026
    Indolent systemic mastocytosis (ISM) is a rare cause of skeletal fragility. In this study, patients with ISM showed a markedly higher prevalence of biconcave vertebral fractures compared with primary osteoporosis. Assessing fracture morphology may aid in differentiating ISM, reducing diagnostic delay, and guiding appropriate management. PURPOSE: Indolent systemic mastocytosis (ISM) is a rare disorder frequently associated with bone fragility and vertebral fractures (VFx). While the morphology of VFx has been studied in other metabolic bone diseases (e.g., osteomalacia), its role in ISM remains unclear. We aimed to evaluate the prevalence of specific VFx morphologies in ISM and assess their potential diagnostic value compared with primary osteoporosis (OP). METHODS: We retrospectively enrolled adults with ISM and VFx, diagnosed according to WHO and ICC criteria. To increase statistical power, each ISM case was compared with two controls with OP. Clinical, densitometric, and laboratory data were collected. VFx were assessed on lateral spine X-rays (T4-L4) using Genant's criteria and categorized as wedge or biconcave. RESULTS: Sixty-six patients were included: 22 with ISM and 44 with OP. ISM patients were younger (68 ± 8 vs. 77 ± 7 years, p < 0.001) and more frequently male (32% vs. 7%, p = 0.043). ISM patients had more VFx (median 4 vs. 3, p = 0.039) and a higher proportion of biconcave VFx (80% vs. 22%, p < 0.001). ROC analysis showed high discriminatory power for the number and proportion of biconcave VFx (AUC 0.878 and AUC 0.919, respectively) in distinguishing ISM from OP, with optimal cut-offs of > 2 biconcave VFx or > 50% of total VFx. These findings remained consistent after adjustment for age and sex. CONCLUSION: Multiple biconcave VFx are significantly associated with ISM and may help differentiate it from primary OP. Assessment of fracture morphology could reduce diagnostic delay and guide appropriate management in patients with vertebral fragility fractures.
  • Outcomes of patients with de novo and secondary acute myeloid leukaemia treated with front-line hypomethylating agents and venetoclax: A retrospective Italian study
    Ilaria Tanasi, Edoardo Tamellini, Elena Marchetti, Eleonora De Bellis, Cristina Ancora, Francesco Angotzi, Davide Facchinelli, Francesca Capraro, Giulia Battaglia, Alessandra Sperotto, Michele Gottardi, Matteo Leoncin, Mauro Krampera, Mario Tiribelli, Carmela Gurrieri
    British Journal of Haematology, 2026
    The data that support the findings of this study are available from the corresponding author upon reasonable request.
  • Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia
    Calogero Vetro, Bruno Garibaldi, Francesco Grimaldi, Patrizia Chiusolo, Carla Filì, Carola Riva, Valeria Cardinali, Marinunzia Franciosa, Federica Pilo, Raffaele Palmieri, Lorenzo Esposito, Diego Menotti, Salvatore Perrone, Antonino Mulè, Caterina Alati, Ernesto Vigna, Michela Dargenio, De De Luca, Alessandra Sperotto, Ilaria Tanasi, Cristina Papayannidis, Matteo Molica, Paola Minetto, Giorgia Battipaglia, Mara Memoli, Prassede Salutari, Lorenzo Brunetti, Elisabetta Todisco, Ivana Lotesoriere, Alessandro Isidori, Giuseppe Alberto Palumbo, Mario Annunziata, Michele Gottardi, Massimo Gentile, Maria Paola Martelli, Debora Capelli, Massimo Martino, Marco Rossi, Felicetto Ferrara, Adriano Venditti, Claudio Romani, Sara Galimberti, Anna Candoni, Luana Fianchi, Livio Pagano, Giovanni Marconi, Roberto Massimo Lemoli, Francesco Di Raimondo, Atto Billio, Fanny Erika Palumbo, Fabrizio Pane, Andrea Duminuco, Fabio Guolo
    Blood Cancer Journal, 2025
    Initial evidence of CPX-351 activity in patients younger than 60 years emerged from a phase I trial [ 1 ]; however, subsequent pivotal phase III trial focused on older patients (≥60 years), where CPX-351 demonstrated superiority over conventional ‘7 + 3’ induction, in in secondary acute myeloid leukemia (sAML), including therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC), showing higher overall response rates (ORR), improved overall survival (OS) and increased haematopoetic stem cell transplantation (HSCT) rate [ 2 ].
  • Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia(Blood Cancer Journal, 10.1038/s41408-025-01394-7)
    Calogero Vetro, Bruno Garibaldi, Francesco Grimaldi, Patrizia Chiusolo, Carla Filì, Carola Riva, Valeria Cardinali, Marinunzia Franciosa, Federica Pilo, Raffaele Palmieri, Lorenzo Esposito, Diego Menotti, Salvatore Perrone, Antonino Mulè, Caterina Alati, Ernesto Vigna, Michela Dargenio, Giulia De Luca, Alessandra Sperotto, Ilaria Tanasi, Cristina Papayannidis, Matteo Molica, Paola Minetto, Giorgia Battipaglia, Mara Memoli, Prassede Salutari, Lorenzo Brunetti, Elisabetta Todisco, Ivana Lotesoriere, Alessandro Isidori, Giuseppe Alberto Palumbo, Mario Annunziata, Michele Gottardi, Massimo Gentile, Maria Paola Martelli, Debora Capelli, Massimo Martino, Marco Rossi, Felicetto Ferrara, Adriano Venditti, Claudio Romani, Sara Galimberti, Anna Candoni, Luana Fianchi, Livio Pagano, Giovanni Marconi, Roberto Massimo Lemoli, Francesco Di Raimondo, Atto Billio, Fanny Erika Palumbo, Fabrizio Pane, Andrea Duminuco, Fabio Guolo
    Blood Cancer Journal, 2025
    In this article, the author Lorenzo Esposito should have affiliations 3 and 11 and Massimo Gentile should have affiliations 16 and 27. The name De De Luca should be corrected to Giulia De Luca Lorenzo Brunetti has an incorrect affiliation. The correct affiliations are: a) Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy b) Clinica di Ematologia, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy Debora Capelli also has an incorrect affiliation. The correct one is: Clinica di Ematologia, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy Additionally, affiliations 6 and 31 in the current manuscript should therefore be merged, as they refer to the same institution.
  • PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study
    Alessandra D’Addio, Michela Rondoni, Marzia Salvucci, Giovanni Marconi, Massimiliano Bonifacio, Ilaria Tanasi, Omar Perbellini, Giuseppe Carli, Patrizia Tosi, Simona Tomassetti, Giovanni Poletti, Evita Massari, Marco Rosetti, Elisabetta Fabbri, Chiara Zingaretti, Alessandro Lucchesi, Maria Teresa Bochicchio, Giorgia Simonetti, Mauro Krampera, Francesco Lanza
    Annals of Hematology, 2025
    The prevalence of paroxysmal nocturnal hemoglobinuria (PNH) clones is little investigated in myeloproliferative neoplasms (MPN) patients. The aim of this multicenter study was to evaluate the prevalence of PNH clones (glycosyl-phosphatidyl-inositol lacking) in 119 Ph- negative MPN patients having anemia, LDH elevation, asthenia and history of thrombosis. All the participating centers performed the standardized diagnostic test by using a single lyophilized template for granulocytes, monocytes, and erythrocytes. Next generation sequencing (NGS) was performed in 2 PNH-positive MPN cases and 13 PNH-negative MPN. The prevalence of PNH positive clones was 3.23% (n. 3 patients). All three patients had splenomegaly; none of them had thrombosis. One patient affected by CALR mutated essential thrombocytopenia, had a small clone (0.52%), clinically irrelevant; one patient affected by JAK2 V617F primary myelofibrosis (PMF) showed a PNH clone of 89.8%, severe anemia and hemoglobinuria and started eculizumab therapy; the third patient affected by CALR mutated PMF showed a PNH clone of 92.6% but without severe anemia and breakthrough hemolysis and eculizumab therapy was not undertaken. PIGA deletion was detected in PNH-positive cases along with mutations of myeloid-related genes. These data seem to suggest an association of CALR mutation and JAK2 V617F mutation with PNH positive clones suggesting that the worsening of malignant process may be associated with the acquisition of multiple genetic mutations. Clinical Trial Registration : NCT06159816.
  • Safety and efficacy of extended venom immunotherapy maintenance intervals in mastocytosis
    Giovanna Sfriso, Matteo Martini, Maria Beatrice Bilò, Maria Angiola Crivellaro, Marina Mauro, Erminia Ridolo, Carla Lombardo, Maria Teresa Costantino, Marcello Cilia, Donatella Bignardi, Fabio Lodi Rizzini, Irene Martignago, Francesco Murzilli, Elisabetta Favero, Giovanni Marchi, Federico Reccardini, Elisa Boni, Valentina Gueli, Francesca Norelli, Ilaria Tanasi, Andrea Bernardelli, Francesco Olivieri, Patrizia Bonadonna
    Journal of Allergy and Clinical Immunology in Practice, 2025
  • New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers
    Giulia Battaglia, Davide Lazzarotto, Ilaria Tanasi, Carmela Gurrieri, Laura Forlani, Endri Mauro, Francesca Capraro, Giulia Ciotti, Eleonora De Bellis, Chiara Callegari, Luca Tosoni, Matteo Fanin, Gian Luca Morelli, Claudia Simio, Cristina Skert, Michele Gottardi, Francesco Zaja, Eleonora Toffoletti, Daniela Damiani, Renato Fanin, Mario Tiribelli
    Journal of Clinical Medicine, 2025
    Background: Nucleophosmin-1 (NPM1) mutation accounts for 30% of acute myeloid leukemia (AML) cases and defines either low- or intermediate-risk AML, depending on FLT3-ITD mutation. New combination regimens (NCRs), adding midostaurin and gemtuzumab ozogamicin (GO) to the 3 + 7 scheme, are commonly used, though there are no data that compare NCRs with intensive induction chemotherapy. Methods: To evaluate the efficacy and safety of NCRs and FLAI in NPM1+ AML, we retrospectively analyzed 125 patients treated with FLAI (n = 53) or NCRs (n = 72) at seven Italian Centers. Results: The median age was 61 years and 51/125 (41%) were FLT3-ITD+. The complete remission (CR) rate was 77%, slightly better with NCRs (83% vs. 68%; p = 0.054). NCRs yielded a superior median overall survival (OS) (not reached (NR) vs. 27.3 months; p = 0.002), though the median event-free survival (EFS) was similar (NR vs. 20.5 months; p = 0.07). In low-risk AML, CR was higher in NCRs (94% vs. 72%, p = 0.02), as were median OS (NR vs. 41.6 months; p = 0.0002) and EFS (NR vs. 17.8 months; p = 0.0085). In intermediate-risk AML (FLT3-ITD+), there were no differences in CR (60% vs. 71%; p = 0.5), OS (p = 0.27), or EFS (p = 0.86); only allogeneic transplantation improved OS (NR vs. 13.4 months; p = 0.005), regardless of induction regimen. The safety profile was similar, except for delayed platelet recovery with FLAI (22 vs. 18 days; p = 0.0024) and higher-grade II–IV gastrointestinal toxicity with NCRs (43% vs. 18.8%; p = 0.0066). Conclusions: Our data suggest the superiority of NCRs over FLAI in low-risk patients, while all outcomes were comparable in intermediate-risk patients, a setting in which only transplants positively impacted on survival.
  • Mast Cell Disorders and Hymenoptera Venom-Triggered Anaphylaxis: Evaluation and Management
    Nathan A. Boggs, Ilaria Tanasi, Karin Hartmann, Roberta Zanotti, David Gonzalez-de-Olano
    Journal of Allergy and Clinical Immunology in Practice, 2025
  • Safety of Drug Provocation Tests in Adults With and Without Clonal Mast Cell Disorders
    Francesca Nalin, Bianca Olivieri, Francesco Olivieri, Elisa Olivieri, Roberta Zanotti, Ilaria Tanasi, Andrea Bernardelli, Massimiliano Bonifacio, Francesca Norelli, Giorgia Marta, Valentina Gueli, Giovanna Sfriso, Patrizia Bonadonna
    Allergy European Journal of Allergy and Clinical Immunology, 2025
    BackgroundMastocytosis is a clonal mast cell disorder (CMD) characterized by the proliferation and accumulation of mast cells (MC) in different tissues. Anaphylaxis, resulting from massive MC activation and mediators' release, is reported in 22%–49% of mastocytosis cases, with drugs being potential triggers. Proper counseling on drug safety is crucial. We aim to demonstrate that, after a careful evaluation of clinical history and allergic work‐up, drug provocation tests (DPT) are a safe and effective diagnostic tool in patients with CMD.MethodsWe enrolled 104 CMD patients with a suspicion of drug hypersensitivity reactions (DHR) or without known tolerated drugs and 100 control patients with DHR. The types of DHR and the results of DPT were compared between CMD and control groups.ResultsIn both groups, previous DHR was mostly represented by skin reactions (46.4% in CMD and 82.9% in the control group); the most involved drugs were aminopenicillins and nonsteroidal anti‐inflammatory drugs (NSAIDs). We performed 250 DPTs in the CMD group and 231 in the control group; challenges were well tolerated in both groups, except for 6 skin reactions: 1 in the CMD group (1.0%) and 5 in the control group (5%).ConclusionDrug challenge is a safe and effective diagnostic tool in patients with CMD. Moreover, patients that have never had adverse reactions to NSAIDs or antibiotics before the diagnosis of CMD do not need to undergo challenge tests. In contrast, patients with a history of reactions should avoid the culprit drugs and undergo DPT to identify a safe alternative drug.
  • Successful rechallenge with azacytidine and venetoclax after sustained treatment-free remission in a relapsed acute myeloid leukemia patient: a case report
    E. Tamellini, C. Simio, A. Bernardelli, I. Ferrarini, A. Vatteroni, A. Moioli, V. Macaluso, E. Marchetti, I. Tanasi
    Annals of Hematology, 2024
  • Underlying systemic mastocytosis in patients with unexplained osteoporosis: score proposal
    Ilaria Tanasi, Lara Crosera, Francesco Taus, Giovanni Orsolini, Giovanni Adami, Francesco Olivieri, Andrea Bernardelli, Patrizia Bonadonna, Francesca Nalin, Stefania Sella, Sandro Giannini, Yihui Liu, Francesco Mannelli, Fiorenza Vanderwert, Massimiliano Bonifacio, Mauro Krampera, Maurizio Rossini, Jonathan J. Lyons, Roberta Zanotti
    Bone, 2024
  • Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis
    Mariarita Sciumè, Fabio Serpenti, Roberta Zanotti, Patrizia Bonadonna, Ilaria Tanasi, Lara Crosera, Chiara Elena, Francesco Mannelli, Francesca Crupi, Cristina Papayannidis, Chiara Sartor, Simona Soverini, Michela Rondoni, Cristina Eller‐Vainicher, Valerio Pravettoni, Federica Rivolta, Silvia Alberti Violetti, Giorgio Alberto Croci, Anna Chiara Migliorini, Niccolò Bolli, Diana Giannarelli, Federica Irene Grifoni
    Hematological Oncology, 2024
  • BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study
    Francesco Malfona, Ilaria Tanasi, Matteo Piccini, Cristina Papayannidis, Vincenzo Federico, Valentina Mancini, Elisa Roncoroni, Elisabetta Todisco, Simona Bianchi, Giulia Ciotti, Patrizia Chiusolo, Massimo Gentile, Valentina Gianfelici, Fabio Giglio, Michele Malagola, Antonino Mulé, Francesco Saraceni, Calogero Vetro, Francesco Zallio, Luca Vincenzo Cappelli, Giovanni Pizzolo, Robin Foà, Massimiliano Bonifacio, Sabina Chiaretti
    Haematologica, 2024
  • Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study
    Darina Ocadlikova, Federico Lussana, Nicola Fracchiolla, Massimiliano Bonifacio, Lidia Santoro, Mario Delia, Sabina Chiaretti, Crescenza Pasciolla, Alessandro Cignetti, Fabio Forghieri, Francesco Grimaldi, Giulia Corradi, Letizia Zannoni, Stefania De Propris, Gian Maria Borleri, Ilaria Tanasi, Jayakumar Vadakekolathu, Sergio Rutella, Anna Rita Guarini, Robin Foà, Antonio Curti, and
    British Journal of Haematology, 2023
  • Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts
    Luca Lanino, Francesco Restuccia, Alessandra Perego, Marta Ubezio, Bruno Fattizzo, Marta Riva, Angela Consagra, Pellegrino Musto, Daniela Cilloni, Esther Natalie Oliva, Raffaele Palmieri, Antonella Poloni, Catello Califano, Isabella Capodanno, Federico Itri, Chiara Elena, Claudio Fozza, Fabrizio Pane, Anna Maria Pelizzari, Massimo Breccia, Francesco Di Bassiano, Elena Crisà, Dario Ferrero, Valentina Giai, Daniela Barraco, Antonella Vaccarino, Davide Griguolo, Paola Minetto, Martina Quintini, Stefania Paolini, Grazia Sanpaolo, Mariarosaria Sessa, Monica Bocchia, Nicola Di Renzo, Elisa Diral, Livia Leuzzi, Angelo Genua, Attilio Guarini, Alfredo Molteni, Barbara Nicolino, Ubaldo Occhini, Giulia Rivoli, Roberto Bono, Anna Calvisi, Andrea Castelli, Eros Di Bona, Ambra Di Veroli, Felicetto Ferrara, Luana Fianchi, Sara Galimberti, Daniele Grimaldi, Monia Marchetti, Marianna Norata, Marco Frigeni, Rosaria Sancetta, Carmine Selleri, Ilaria Tanasi, Patrizia Tosi, Mauro Turrini, Laura Giordano, Carlo Finelli, Paolo Pasini, Ilaria Naldi, Valeria Santini, Matteo Giovanni Della Porta, and
    American Journal of Hematology, 2023
  • Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry
    Vanessa E. Kennedy, Cecelia Perkins, Andreas Reiter, Mohamad Jawhar, Johannes Lübke, Hanneke C. Kluin-Nelemans, William Shomali, Cheryl Langford, Justin Abuel, Olivier Hermine, Marek Niedoszytko, Aleksandra Gorska, Andrzej Mital, Patrizia Bonadonna, Roberta Zanotti, Ilaria Tanasi, Mattias Mattsson, Hans Hagglund, Massimo Triggiani, Akif Selim Yavuz, Jens Panse, Deborah Christen, Marc Heizmann, Khalid Shoumariyeh, Sabine Müller, Chiara Elena, Luca Malcovati, Nicolas Fiorelli, Friederike Wortmann, Vladan Vucinic, Knut Brockow, Christos Fokoloros, Sotirios G. Papageorgiou, Christine Breynaert, Dominique Bullens, Michael Doubek, Anja Ilerhaus, Irena Angelova-Fischer, Oleksii Solomianyi, Judit Várkonyi, Vito Sabato, Axel Rüfer, Tanja Daniela Schug, Maud A. W. Hermans, Anna Belloni Fortina, Francesca Caroppo, Horia Bumbea, Theo Gulen, Karin Hartmann, Hanneke Oude Elberink, Juliana Schwaab, Michel Arock, Peter Valent, Wolfgang R. Sperr, Jason Gotlib
    Blood Advances, 2023
  • Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia–like or acute lymphoblastic leukemia–like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study
    Davide Lazzarotto, Ilaria Tanasi, Antonella Vitale, Matteo Piccini, Michelina Dargenio, Fabio Giglio, Fabio Forghieri, Nicola Fracchiolla, Marco Cerrano, Elisabetta Todisco, Cristina Papayannidis, Matteo Leoncin, Marzia Defina, Fabio Guolo, Crescenza Pasciolla, Mario Delia, Patrizia Chiusolo, Antonino Mulè, Anna Candoni, Massimiliano Bonifacio, Giovanni Pizzolo, Robin Foà
    Annals of Hematology, 2023
  • Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project
    Giacomo Coltro, Emanuela Sant'Antonio, Giuseppe A. Palumbo, Francesco Mannelli, Valerio De Stefano, Marco Ruggeri, Elena M. Elli, Roberta Zanotti, Oscar Borsani, Irene Bertozzi, Andrea Duminuco, Silvia Betti, Giuseppe Carli, Fabrizio Cavalca, Ilaria Tanasi, Elisa Rumi, Maria L. Randi, Bruno Garibaldi, Giuseppe G. Loscocco, Paola Guglielmelli, Alessandro M. Vannucchi
    Cancer Medicine, 2023
  • Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study
    Michelina Dargenio, Massimiliano Bonifacio, Sabina Chiaretti, Antonella Vitale, Nicola Stefano Fracchiolla, Cristina Papayannidis, Fabio Giglio, Prassede Salutari, Ernesta Audisio, Barbara Scappini, Patrizia Zappasodi, Marzia Defina, Fabio Forghieri, Anna Maria Scattolin, Elisabetta Todisco, Monia Lunghi, Fabio Guolo, Maria Ilaria Del Principe, Mario Annunziata, Davide Lazzarotto, Michele Cedrone, Crescenza Pasciolla, Annalisa Imovilli, Ilaria Tanasi, Silvia Trappolini, Marco Cerrano, Roberta La Starza, Mauro Krampera, Nicola Di Renzo, Anna Candoni, Giovanni Pizzolo, Felicetto Ferrara, Robin Foà
    British Journal of Haematology, 2023
  • The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis
    Francesco Mannelli, Francesca Crupi, Roberta Zanotti, Livio Pagano, Davide Rapezzi, Ilaria Tanasi, Marianna Criscuolo, Massimiliano Bonifacio, Alberto Fresa, Paola Guglielmelli, Alessandro M. Vannucchi
    Therapeutic Advances in Hematology, 2023
  • Update on the Role and Utility of Extracellular Vesicles in Hematological Malignancies
    Riccardo Bazzoni, Ilaria Tanasi, Nice Turazzi, Mauro Krampera
    Stem Cells, 2022
  • Corrigendum: “Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience” (Leukemia Research (2022) 114, (106803), (S0145212622000297), (10.1016/j.leukres.2022.106803))
    Eleonora De Bellis, Silvia Imbergamo, Anna Candoni, Albana Liço, Ilaria Tanasi, Endri Mauro, Federico Mosna, Matteo Leoncin, Manuela Stulle, Davide Griguolo, Stefano Pravato, Livio Trentin, Davide Lazzarotto, Eros Di Bona, Rosaria Sancetta, Elisa Lucchini, Monica Poiani, Clara Palmieri, Francesco Zaja
    Leukemia Research, 2022
  • Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study
    Marco Cerrano, Massimiliano Bonifacio, Matteo Olivi, Antonio Curti, Michele Malagola, Michelina Dargenio, Anna Maria Scattolin, Cristina Papayannidis, Fabio Forghieri, Carmela Gurrieri, Ilaria Tanasi, Patrizia Zappasodi, Roberta La Starza, Nicola Stefano Fracchiolla, Patrizia Chiusolo, Luisa Giaccone, Maria Ilaria Del Principe, Fabio Giglio, Marzia Defina, Claudio Favre, Carmelo Rizzari, Barbara Castella, Giovanni Pizzolo, Felicetto Ferrara, Sabina Chiaretti, Robin Foà
    Haematologica, 2022
  • Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience
    Eleonora De Bellis, Silvia Imbergamo, Anna Candoni, Albana Liço, Ilaria Tanasi, Endri Mauro, Federico Mosna, Matteo Leoncin, Manuela Stulle, Davide Griguolo, Stefano Pravato, Livio Trentin, Davide Lazzarotto, Eros Di Bona, Renato Bassan, Elisa Lucchini, Monica Poiani, Clara Palmieri, Francesco Zaja
    Leukemia Research, 2022
  • A multidisciplinary diagnostic approach reveals a higher prevalence of indolent systemic mastocytosis: 15-years’ experience of the gism network
    Roberta Zanotti, Massimiliano Bonifacio, Cecilia Isolan, Ilaria Tanasi, Lara Crosera, Francesco Olivieri, Giovanni Orsolini, Donatella Schena, Patrizia Bonadonna
    Cancers, 2021
  • The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population
    Massimiliano Bonifacio, Mario Tiribelli, Maria Cristina Miggiano, Elisabetta Abruzzese, Gianni Binotto, Luigi Scaffidi, Maddalena Cordioli, Daniela Damiani, Eros Di Bona, Malgorzata Monika Trawinska, Ilaria Tanasi, Maria Vittoria Dubbini, Vanessa Velotta, Giulia Ceccarelli, Elisabetta Pierdomenico, Mariella Lo Schirico, Gianpietro Semenzato, Marco Ruggeri, Renato Fanin, Evelina Tacconelli, Giovanni Pizzolo, Mauro Krampera
    Cancer Medicine, 2021
  • Safety of local anesthesia and prevalence of hypersensitivity reactions in adult patients with clonal mast cell diseases: A retrospective single-center study
    Ilaria Tanasi, Elisa Olivieri, Margherita Oberti, Giuseppe Lucchini, Fabiana Furci, Roberta Zanotti, Patrizia Bonadonna
    Journal of Allergy and Clinical Immunology in Practice, 2021
  • Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis
    Carlo Visco, Francesca Pregnolato, Isacco Ferrarini, Beatrice De Marco, Valentina Bonuomo, Eugenio Sbisà, Costanza Fraenza, Andrea Bernardelli, Ilaria Tanasi, Francesca Maria Quaglia, Mauro Krampera
    Critical Reviews in Oncology Hematology, 2021
  • Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series
    Ilaria Tanasi, Massimiliano Bonifacio, Miriam Pizzolato, Federica Irene Grifoni, Mariarita Sciumè, Chiara Elena, Pietro Benvenuti, Francesco Mannelli, Roberta Parente, Donatella Schena, Luigi Scaffidi, Patrizia Bonadonna, Cristina Papayannidis, Michela Rondoni, Marianna Criscuolo, Alessandro M. Vannucchi, Massimo Triggiani, Giovanni Martinelli, Mauro Krampera, Roberta Zanotti
    British Journal of Haematology, 2021
  • Bone marrow mastocytosis: A diagnostic challenge
    Roberta Zanotti, Ilaria Tanasi, Andrea Bernardelli, Giovanni Orsolini, Patrizia Bonadonna
    Journal of Clinical Medicine, 2021
  • Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study
    Javier I Muñoz-González, Iván Álvarez-Twose, María Jara-Acevedo, Roberta Zanotti, Cecelia Perkins, Mohamad Jawhar, Wolfgang R Sperr, Khalid Shoumariyeh, Juliana Schwaab, Georg Greiner, Ana Henriques, Carolina Caldas, Carlos Fernández-Giménez, Laura Sánchez-Muñoz, Andrea Mayado, Alba Pérez-Pons, Annette Schmitt-Graeff, Justus Duyster, Ilaria Tanasi, Francesco Olivieri, Elvira Mora-Casterá, Irene Luna, Leonor Senent, Maria-Helena Bañas, Amanda Nuñez-García, Manuel Jurado-Chacón, Guillermo Martín-Sánchez, Enrique Colado, Blanca Xicoy, Georgina Gener-Ricós, Jason Gotlib, Patrizia Bonadonna, Andreas Reiter, Peter Valent, Andrés C García-Montero, Alberto Orfao
    Lancet Haematology, 2021
  • The Role of Notch and Wnt Signaling in MSC Communication in Normal and Leukemic Bone Marrow Niche
    Paul Takam Kamga, Riccardo Bazzoni, Giada Dal Collo, Adriana Cassaro, Ilaria Tanasi, Anna Russignan, Cristina Tecchio, Mauro Krampera
    Frontiers in Cell and Developmental Biology, 2021
  • Systemic mastocytosis: Multidisciplinary approach
    Roberta Zanotti, Massimiliano Bonifacio, Ilaria Tanasi, Donatella Schena, Giovanni Orsolini, Morena Tebaldi, Lara Crosera, Francesca Mastropaolo, Elisa Olivieri, Patrizia Bonadonna
    Mediterranean Journal of Hematology and Infectious Diseases, 2021
  • Extracellular Vesicle-Dependent Communication Between Mesenchymal Stromal Cells and Immune Effector Cells
    Riccardo Bazzoni, Paul Takam Kamga, Ilaria Tanasi, Mauro Krampera
    Frontiers in Cell and Developmental Biology, 2020
  • Oncogenic mutations of MYD88 and CD79B in diffuse large B-cell lymphoma and implications for clinical practice
    Carlo Visco, Ilaria Tanasi, Francesca Maria Quaglia, Isacco Ferrarini, Costanza Fraenza, Mauro Krampera
    Cancers, 2020
  • Small molecule inhibitors of microenvironmental wnt/β-catenin signaling enhance the chemosensitivity of acute myeloid leukemia
    Paul Takam Kamga, Giada Dal Collo, Adriana Cassaro, Riccardo Bazzoni, Pietro Delfino, Annalisa Adamo, Alice Bonato, Carmine Carbone, Ilaria Tanasi, Massimiliano Bonifacio, Mauro Krampera
    Cancers, 2020
  • High-throughput analysis and functional interpretation of extracellular vesicle content in hematological malignancies
    Ilaria Tanasi, Annalisa Adamo, Paul Takam Kamga, Riccardo Bazzoni, Mauro Krampera
    Computational and Structural Biotechnology Journal, 2020
  • Notch signaling molecules as prognostic biomarkers for acute myeloid leukemia
    Paul Takam Kamga, Giada Dal Collo, Federica Resci, Riccardo Bazzoni, Angela Mercuri, Francesca Maria Quaglia, Ilaria Tanasi, Pietro Delfino, Carlo Visco, Massimiliano Bonifacio, Mauro Krampera
    Cancers, 2019
  • Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements
    Ilaria Tanasi, Ibrahima Ba, Nicolas Sirvent, Thorsten Braun, Wendy Cuccuini, Paola Ballerini, Nicolas Duployez, Aline Tanguy-Schmidt, Jérôme Tamburini, Sébastien Maury, Eric Doré, Chantal Himberlin, Cédric Duclos, Patrice Chevallier, Philippe Rousselot, Massimiliano Bonifacio, Hélène Cavé, André Baruchel, Hervé Dombret, Jean Soulier, Judith Landman-Parker, Nicolas Boissel, Emmanuelle Clappier
    Blood, 2019